
Opinion|Videos|August 7, 2024
Reducing Treatment Burden in IBD with At-Home Therapy Options
Author(s)Jean-Frederic Colombel, MD
Jean-Frederic Colombel, MD, offers insights into subcutaneous infliximab-dyyb injection, detailing its administration and approved indications for ulcerative colitis and Crohn's disease.
Advertisement
Episodes in this series
- The FDA has now approved a subcutaneous infliximab injection for IBD. Can you provide an overview of subcutaneous infliximab-dyyb injection? What is the significance of this approval?
- How could this impact patients with UC and CD?
- What are the indications for subcutaneous infliximab-dyyb injection?
- When and how can this therapy be started?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
New Dyslipidemia Guidelines Reveal Significant Gap in LDL-C and LLT Treatment Goals
2
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD
3
Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS
4
Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape?
5












































































